About KEYTRUDA SC
*Based on recommended dose. This does not account for all aspects of treatment. Actual clinic time may vary.
KEYTRUDA SC (pembrolizumab) demonstrated non-inferior PK results and faster administration vs KEYTRUDA IV1,2,3
KEYTRUDA (pembrolizumab) 395 mg solution for injection Prescribing Information [External link] | KEYTRUDA (pembrolizumab) 790 mg solution for injection Prescribing Information [External link] | KEYTRUDA (pembrolizumab) 25 mg/mL Concentrate Solution for Infusion Prescribing Information [External link]
KEYTRUDA SC provides two dosing options and is a ready-to-use solution which doesn’t require dilution1
Vials shown to scale, not actual size.
†Does not account for all aspects of treatment. Actual clinic time may vary.
Support and Resources
Dosing, Storage and
Administration Guide
To order a printed version, please contact us at msdukoncology@msd.com
Dosing and Administration Poster
To order a printed version, please contact us at msdukoncology@msd.com
Explore the KEYTRUDA SC Training and Resources page
KEYTRUDA SCTM is licensed for use in adult patients across most KEYTRUDA IV indications, whether alone or in combination with other therapies.1,2 One such indication is: KEYTRUDA IV and KEYTRUDA SC, in combination with pemetrexed and platinum chemotherapy, are each indicated for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma in adults whose tumours have no EGFR- or ALK-positive mutations.1,2
Please consult the SmPC for the full list of indications and further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.
KEYTRUDA SC is for adult use only. The safety and efficacy of KEYTRUDA SC in children below 18 years of age have not been established.1
The approved indications for KEYTRUDA SC have been established based on the MK-3475A-D77 study, which demonstrated non-inferior pharmacokinetics, and comparable efficacy and safety profiles between KEYTRUDA SC and KEYTRUDA.1
Please refer to individual product SmPCs for full information about dosing, preparation and administration.
Abbreviations
ALK = anaplastic lymphoma kinase; EGFR = epidermal growth factor receptor ; IV = intravenous; PK = pharmacokinetic; Q3W = every 3 weeks; Q6W = every 6 weeks; SmPC = Summary of Product Characteristics
References
- KEYTRUDA (pembrolizumab) Solution for Injection Summary of Product Characteristics (395 mg and 790 mg).
- KEYTRUDA (pembrolizumab) 25 mg/mL Concentrate Solution for Infusion Summary of Product Characteristics.
- Felip E, et al. Ann Oncol 2025;36:775–785.
Supporting documentation
KEYTRUDA (pembrolizumab) 395 mg solution for injection Prescribing Information [External link]
KEYTRUDA (pembrolizumab) 790 mg solution for injection Prescribing Information [External link]
KEYTRUDA (pembrolizumab) 25 mg/mL Concentrate Solution for Infusion Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
